Jan. 26, 2018:

Abstracts from two Big Ten Cancer Research Consortium studies were accepted as trials in progress at recent meetings of the American Society of Clinical Oncology. BTCRC-ESO14-012 was accepted to the Gastrointestinal Cancers Symposium and BTCRC-LUN16-081 was accepted to the ASCO-SITC Clinical Immuno-Oncology Symposium. Both meetings were held this month in San Francisco.

Study author Hirva Mamdani, MD, completed her fellowship at Indiana University Melvin and Bren Simon Cancer Center.

A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012. See abstract.

• Session Type: Trials in Progress Poster Session
• Citation: J Clin Oncol 36, 2018 (suppl 4S; abstr TPS194)
• Authors: Hirva Mansurali Mamdani, Laith I. Abushahin, Bryan J. Schneider, Rozina A. Chowdhery, Borys Hrinczenko, Ahran Lee, Susan M. Perkins, Kenneth Kesler, Shadia Ibrahim Jalal; Indiana University, Indianapolis, IN; University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA; Weill Cornell Medical College, New York, NY; University of Illinois Hospital and Health Sciences System, Chicago, IL; Michigan State University, Lansing, MI; Big Ten Cancer Research Consortium, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN

BTCRC-LUN16-081

Study sponsor-investigator and author Greg Durm, MD, is a medical oncologist at Indiana University Melvin and Bren Simon Cancer Center.

Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC). See abstract.

• Session Type: Trials in Progress Poster Session
• Citation: J Clin Oncol 36, 2018 (suppl 5S; abstr TPS179)
• Authors: Greg Andrew Durm, Susan M. Perkins, Nasser H. Hanna; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University, Indianapolis, IN

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The goal of the Big Ten Cancer Research Consortium is to create a unique team-research culture to drive science rapidly from ideas to new approaches to cancer treatment. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to almost 9,500 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org.